EMA's CHMP Recommended Five Extensions Of Indication For Medicines Bimervax, Dupixent, Keytruda

EMA's CHMP:

• EMA'S CHMP: RECOMMENDED FIVE EXTENSIONS OF INDICATION FOR MEDICINES BIMERVAX, DUPIXENT, KEYTRUDA

• EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR IMAAVY (NIPOCALIMAB)

• EMA'S CHMP: POSITIVE OPINION WAS ADOPTED FOR KYINSU (INSULIN ICODEC / SEMAGLUTIDE)

• EMA'S CHMP: FOLLOWING RE-EXAMINATION, RECOMMENDED GRANTING MARKETING AUTHORISATION FOR WINLEVI (CLASCOTERONE)

• EMA'S CHMP: WITHDRAWAL OF INITIAL MARKETING AUTHORISATION APPLICATION FOR IOVANCE BIOTHERAPEUTICS B.V.'S AMTAGVI MEDICINE